{"id":555,"date":"2026-02-27T14:09:20","date_gmt":"2026-02-27T12:09:20","guid":{"rendered":"http:\/\/example.test\/?page_id=555"},"modified":"2026-03-25T11:06:52","modified_gmt":"2026-03-25T09:06:52","slug":"glp-1-vs-gip-vs-glucagon-receptors","status":"publish","type":"page","link":"https:\/\/life-peptide.com\/ro\/glp-1-vs-gip-vs-glucagon-receptors\/","title":{"rendered":"Receptori GLP-1 vs GIP vs glucagon"},"content":{"rendered":"<h1 class=\"wp-block-heading has-text-align-center\">Receptori GLP-1 vs GIP vs glucagon<\/h1>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\"><strong><strong>Arhitectur\u0103 structural\u0103 \u0219i diferen\u021be \u00een semnalizarea pe termen lung \u00een cercetarea metabolic\u0103<\/strong><\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Receptorii GLP-1, GIP \u0219i glucagon apar\u021bin familiei de receptori cupla\u021bi cu proteina G (GPCR) de clas\u0103 B \u0219i joac\u0103 roluri centrale \u00een semnalizarea metabolic\u0103. De\u0219i sunt \u00eenrudi\u021bi structural, ace\u0219ti receptori difer\u0103 semnificativ \u00een distribu\u021bia tisular\u0103, biasul semnaliz\u0103rii intracelulare \u0219i func\u021bia fiziologic\u0103.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00cen\u021belegerea diferen\u021belor la nivel de receptor este esen\u021bial\u0103 atunci c\u00e2nd se compar\u0103:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Agoni\u0219ti ai receptorilor GLP-1 (de ex., semaglutid\u0103)<\/li>\n\n\n\n<li>Agoni\u0219ti duali GLP-1\/GIP (ex. tirzepatid\u0103)<\/li>\n\n\n\n<li>Agoni\u0219ti tripli GLP-1\/GIP\/glucagon (de ex., retatrutid\u0103)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Pentru o imagine de ansamblu mai larg\u0103 a acestor compu\u0219i, vezi <a href=\"\/ro\/glp-1-metabolic-research-guide\/\" data-type=\"page\" data-id=\"529\">Ghid de cercetare metabolic\u0103 GLP-1<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>1. Receptor GLP-1 (GLP1R)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clas\u0103 receptor<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GPCR clasa B (familia secretinei)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Distribu\u021bia tisular\u0103<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Celule beta pancreatice<\/li>\n\n\n\n<li>Tract gastrointestinal<\/li>\n\n\n\n<li>Troncul cerebral \u0219i hipotalamusul<\/li>\n\n\n\n<li>\u021aesut cardiovascular<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Activarea receptorului GLP-1 stimuleaz\u0103 \u00een principal cuplarea proteinei Gs, cresc\u00e2nd AMP ciclic intracelular \u0219i activ\u00e2nd proteina kinaz\u0103 A (PKA), ceea ce cre\u0219te secre\u021bia de insulin\u0103 dependent\u0103 de glucoz\u0103 (Drucker, 2018; Nauck &amp; Meier, 2019).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">C\u0103ile de semnalizare secundar\u0103 includ activarea PI3K\/Akt \u0219i ERK, contribuind la supravie\u021buirea celulelor beta \u0219i la modularea apetitului prin intermediul c\u0103ilor sistemului nervos central.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"\/ro\/product\/semaglutide-10-mg\/\" data-type=\"product\" data-id=\"303\">Semaglutid\u0103 <\/a>ac\u021bioneaz\u0103 ca un agonist selectiv al receptorului GLP-1, asigur\u00e2nd o activare \u021bintit\u0103 a acestei c\u0103i incretinice.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>2. Receptor GIP (GIPR)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clas\u0103 receptor<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GPCR de clasa B<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Distribu\u021bia tisular\u0103<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Celule beta pancreatice<\/li>\n\n\n\n<li>\u021aesutul adipos<\/li>\n\n\n\n<li>Regiunile SNC<\/li>\n\n\n\n<li>Tract gastrointestinal<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Similar cu GLP-1R, GIPR se cupleaz\u0103 \u00een principal la proteinele Gs \u0219i cre\u0219te cAMP intracelular. Cu toate acestea, semnalizarea GIP influen\u021beaz\u0103, de asemenea, stocarea lipidic\u0103 a adipocitelor, amplificarea insulinotropic\u0103 \u0219i c\u0103ile de parti\u021bionare a nutrien\u021bilor (Campbell &amp; Drucker, 2013).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">De\u0219i studiile metabolice timpurii au pus sub semnul \u00eentreb\u0103rii rolul GIP \u00een anumite st\u0103ri de rezisten\u021b\u0103 la insulin\u0103, agonismul dual al receptorilor GLP-1\/GIP a demonstrat efecte metabolice \u00eembun\u0103t\u0103\u021bite comparativ cu GLP-1 singur (Frias et al., 2021; Jastreboff et al., 2022).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"\/ro\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid\u0103 <\/a>utilizeaz\u0103 acest mecanism cu doi receptori pentru a extinde modularea c\u0103ii incretinelor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3. Receptorul pentru glucagon (GCGR)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clas\u0103 receptor<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GPCR de clasa B<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Distribu\u021bia tisular\u0103<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ficatul (hepatocitele)<\/li>\n\n\n\n<li>Rinichi<\/li>\n\n\n\n<li>\u021aesutul adipos<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Activarea receptorului de glucagon stimuleaz\u0103 produc\u021bia hepatic\u0103 de glucoz\u0103 \u0219i oxidarea lipidic\u0103 prin semnalizare mediat\u0103 de Gs-cAMP (Habegger et al., 2010). De asemenea, influen\u021beaz\u0103 c\u0103ile de cheltuieli energetice \u0219i reglarea metabolic\u0103 sistemic\u0103.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Spre deosebire de GLP-1R \u0219i GIPR, care moduleaz\u0103 \u00een principal c\u0103ile insulinotropice, activarea receptorilor de glucagon are un efect metabolic hepatic dominant.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"\/ro\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid\u0103 <\/a>\u00eenglobeaz\u0103 activarea receptorilor pentru glucagon pe l\u00e2ng\u0103 semnalizarea receptorilor pentru GLP-1 \u0219i GIP, introduc\u00e2nd o complexitate metabolic\u0103 sistemic\u0103 mai larg\u0103 (Jastreboff et al., 2023).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>4. Compara\u021bie structural\u0103 \u0219i func\u021bional\u0103<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Caracteristic\u0103<\/strong><\/td><td><strong>GLP-1R<\/strong><\/td><td><strong>GIPR<\/strong><\/td><td><strong>GCGR<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Familia de receptori<\/strong><\/td><td>GPCR de clasa B<\/td><td>GPCR de clasa B<\/td><td>GPCR de clasa B<\/td><\/tr><tr><td><strong>Focarul tisular primar<\/strong><\/td><td>Pancreas + SNC<\/td><td>Pancreas + adipos<\/td><td>Ficat<\/td><\/tr><tr><td><strong>Semnalizare dominant\u0103<\/strong><\/td><td>cAMP\/PKA<\/td><td>cAMP + modula\u021bie metabolic\u0103<\/td><td>cAMP + c\u0103i energetice hepatice<\/td><\/tr><tr><td><strong>Rol esen\u021bial \u00een cercetare<\/strong><\/td><td>Semnalizare insulinic\u0103 incretinic\u0103<\/td><td>Sinergia incretinelor<\/td><td>Consumul energetic \u0219i metabolismul hepatic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">De\u0219i to\u021bi cei trei receptori activeaz\u0103 cascadele de semnalizare ale AMPc, diferen\u021bele \u00een ceea ce prive\u0219te distribu\u021bia tisular\u0103 \u0219i preferin\u021ba receptorilor determin\u0103 rezultate metabolice fundamental distincte.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>5. Sinergia multi-receptor \u00een agoni\u0219tii dubli \u0219i tripli<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Activarea unui singur receptor (doar GLP-1) produce efecte incretinice focalizate. Activarea dual\u0103 (GLP-1 + GIP) \u00eembun\u0103t\u0103\u021be\u0219te semnalizarea insulinotrop\u0103 \u0219i poate modifica r\u0103spunsul metabolic al adipocitelor (Frias et al., 2021).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Activarea tripl\u0103 a receptorilor adaug\u0103 semnalizarea hepatic\u0103 mediat\u0103 de glucagon, influen\u021b\u00e2nd oxidarea lipidelor \u0219i cheltuielile energetice sistemice (Jastreboff et al., 2023).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Acest strat la nivel de receptor explic\u0103 de ce:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Semaglutida reprezint\u0103 un model selectiv de incretin\u0103<\/li>\n\n\n\n<li>Tirzepatida extinde sinergia incretinic\u0103<\/li>\n\n\n\n<li>Retatrutida introduce modularea metabolic\u0103 sistemic\u0103<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Cre\u0219terea \u021bintelor receptoarelor m\u0103re\u0219te complexitatea semnaliz\u0103rii \u00een aval \u0219i considera\u021biile de modelare experimental\u0103.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>6. SNC vs distribu\u021bie periferic\u0103<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Receptorii GLP-1 sunt puternic exprima\u021bi \u00een regiunile hipotalamice \u0219i ale trunchiului cerebral asociate cu reglarea apetitului (Drucker, 2018). Receptorii GIP sunt, de asemenea, prezen\u021bi \u00een \u021besuturile sistemului nervos central, de\u0219i rolul lor central r\u0103m\u00e2ne \u00een curs de investigare activ\u0103.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Receptorii de glucagon sunt preponderent hepatici, subliniind controlul metabolic periferic mai degrab\u0103 dec\u00e2t reglarea central\u0103 a apetitului.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aceste diferen\u021be de distribu\u021bie contribuie la rezultate mecanice distincte \u00een cercetarea comparativ\u0103 a receptorilor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>7. Considera\u021bii privind proiectarea experimental\u0103<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">C\u00e2nd proiecta\u021bi modele de cercetare metabolic\u0103:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Agoni\u0219tii selectivi ai GLP-1 permit evaluarea controlat\u0103 a c\u0103ii incretinice<\/li>\n\n\n\n<li>Agoni\u0219tii duali necesit\u0103 modelarea interac\u021biunii semnaliz\u0103rii pancreatice \u0219i adipoase<\/li>\n\n\n\n<li>Agoni\u0219tii tripli necesit\u0103 monitorizare metabolic\u0103 hepatic\u0103<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Crosstalk-ul receptorilor \u0219i r\u0103spunsurile endocrine compensatorii trebuie luate \u00een considerare la interpretarea datelor experimentale.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>8. \u00centreb\u0103ri frecvente<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sunt receptorii GLP-1, GIP \u0219i glucagon \u00eenrudi\u021bi structural?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Da. Toate apar\u021bin familiei de GPCR clasa B, dar difer\u0103 \u00een specificitatea pentru liganzi \u0219i expresia tisular\u0103.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>De ce activarea receptorului GIP modific\u0103 rezultatele?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Semnalizarea receptorului GIP influen\u021beaz\u0103 c\u0103ile adipocitare \u0219i insulinotrope, amplific\u00e2nd efectele incretinelor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>De ce s\u0103 includem activarea receptorului pentru glucagon?<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Semnalizarea receptorilor de glucagon afecteaz\u0103 metabolismul hepatic \u0219i cheltuielile energetice sistemice, extinz\u00e2nd domeniul de aplicare al model\u0103rii metabolice.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>9. Referin\u021be \u0219tiin\u021bifice<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Drucker DJ. Mecanisme de ac\u021biune \u0219i aplica\u021bii terapeutice ale peptidei glucagon-like 1. <em>Metabolismul celular<\/em>. 2018.<br>Nauck MA, Meier JJ. Hormonii incretini: Rolul lor \u00een s\u0103n\u0103tate \u0219i boal\u0103. <em>Diabet, Obezitate \u0219i Metabolism<\/em>. 2019.<br>Campbell JE, Drucker DJ. Farmacologie, fiziologie \u0219i mecanisme de ac\u021biune ale hormonilor incretinici. <em>Metabolismul celular<\/em>. 2013.<br>Habegger KM et al. Ac\u021biunile metabolice ale glucagonului revizuite. <em>Nature Reviews Endocrinology<\/em>. 2010.<br>Frias JP \u0219i colaboratorii. Tirzepatid\u0103 versus Semaglutid\u0103 o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 la pacien\u021bii cu diabet de tip 2. <em>New England Journal of Medicine<\/em>. 2021.<br>Jastreboff AM \u0219i colab. Tirzepatid\u0103 o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103 pentru tratamentul obezit\u0103\u021bii. <em>NEJM<\/em>. 2022.<br>Jastreboff AM \u0219i colab. Agonistul receptorilor tripli de hormoni Retatrutid\u0103 pentru obezitate. <em>NEJM<\/em>. 2023.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>10. Compu\u0219i metabolici de cercetare \u00eenruditi<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/ro\/product\/semaglutide-10-mg\/\" data-type=\"product\" data-id=\"309\">Semaglutid\u0103 <\/a>(Agonist al receptorului GLP-1)<\/li>\n\n\n\n<li><a href=\"\/ro\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid\u0103 <\/a>(Agonist dual GLP-1\/GIP)<\/li>\n\n\n\n<li><a href=\"\/ro\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid\u0103 <\/a>(Agonist triplu GLP-1\/GIP\/glucagon)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Naviga\u021bi prin toate compu\u0219ii pe baz\u0103 de incretin\u0103 \u00een <a href=\"\/ro\/category\/peptidi-de-cercetare-metabolica\/\">Categoria de cercetare metabolic\u0103.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>GLP-1 vs GIP vs glucagon receptors Structural architecture &amp; downstream signaling differences in metabolic research GLP-1, GIP, and glucagon receptors belong to the class B G protein\u2013coupled receptor (GPCR) family and play central roles in metabolic signaling. Although structurally related, these receptors differ significantly in tissue distribution, intracellular signaling bias, and physiological function. Understanding receptor-level [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-555","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages\/555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/comments?post=555"}],"version-history":[{"count":4,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages\/555\/revisions"}],"predecessor-version":[{"id":613,"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/pages\/555\/revisions\/613"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/ro\/wp-json\/wp\/v2\/media?parent=555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}